OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting [Yahoo! Finance]
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
OKYO Pharma (NASDAQ:OKYO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
OKYO Pharma Announces Successful Type C Meeting with the FDA
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain